3 Papers
Miao Cui is an academic researcher from Mount Sinai St. Luke's and Mount Sinai Roosevelt. The author has contributed to research in topics: Retrospective cohort study & Acquired immune system. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Nan Wang,Yan Zhan,Linyu Zhu,Zhibing Hou,Feng Liu,Pinhong Song,Feng Qiu,Xiaolin Wang,Xiafei Zou,Deyun Wan,Xiaosong Qian,Shanshan Wang,Yabi Guo,Hao Yu,Miao Cui,Gangling Tong,Yunsheng Xu,Zhihua Zheng,Yingying Lu,Peng Hong,Peng Hong,Peng Hong +21 more
TL;DR: It is concluded that administration of IFN-α2b during the early stage of COVID-19 may induce favorable clinical responses and reduce mortality and accelerated recovery compared to lopinavir/ritonavir (LPV/r) alone.
295
Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19.
Yingying Lu,Feng Liu,Gangling Tong,Feng Qiu,Pinhong Song,Xiaolin Wang,Xiafei Zou,Deyun Wan,Miao Cui,Yunsheng Xu,Zhihua Zheng,Peng Hong,Peng Hong,Peng Hong +13 more
TL;DR: In this article, a cohort of 387 PCR-confirmed COVID-19 patients with quasi-random exposure to interferons and conditional exposure to glucocorticoids was retrospectively analyzed.
SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection.
Yan Zhan,Yufang Zhu,Shanshan Wang,Shijun Jia,Yunling Gao,Yingying Lu,Yingying Lu,Caili Zhou,Ran Liang,Dingwen Sun,Xiaobo Wang,Zhibing Hou,Qiaoqiao Hu,Peng Du,Hao Yu,Chang Liu,Miao Cui,Gangling Tong,Zhihua Zheng,Yunsheng Xu,Linyu Zhu,Jin Cheng,Feng Wu,Yulan Zheng,Peijun Liu,Peng Hong,Peng Hong,Peng Hong +27 more
TL;DR: Wang et al. as discussed by the authors analyzed a prospective cohort of 121 recovered COVID-19 patients from Xiangyang, China at 1-year after diagnosis, and found that participants were still 50% protected against detectable and severe re-infection of WT SARS-CoV-2, respectively, while neutralization levels against B.1.7 and B.351 variants were significantly reduced.